Showing results (1561-1570 of 1,606) with videos related to

Sort By:
Pageof 161
Cancers|March 28, 2025
Evaluating Sorafenib (SORA-2) as Second-Line Treatment for Unresectable Hepatocellular Carcinoma: A European Retrospective Multicenter StudyChristian Möhring, Moritz Berger, Farsaneh Sadeghlar, et al.
World Journal of Gastrointestinal Oncology|December 11, 2023
Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio appear predictive of immune treatment related toxicity in hepatocellular carcinomaSirish Dharmapuri, Umut Özbek, Hiren Jethra, et al.
Hepatology Communications|October 27, 2023
Efficacy and safety of atezolizumab/bevacizumab in patients with HCC after prior systemic therapy: A global, observational studyVincent Joerg, Bernhard Scheiner, Antonio D Alessio, et al.
Journal of Neuro-Oncology|March 4, 2020
Clinical presentation of young people (10-24 years old) with brain tumors: results from the international MOBI-Kids studyAngela Zumel-Marne, Michael Kundi, Gemma Castaño-Vinyals, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|December 28, 2022
Progression patterns and therapeutic sequencing following immune checkpoint inhibition for hepatocellular carcinoma: An international observational studyThomas Talbot, Antonio D'Alessio, Matthias Pinter, et al.
Nature Communications|May 13, 2022
MYC drives aggressive prostate cancer by disrupting transcriptional pause release at androgen receptor targetsXintao Qiu, Nadia Boufaied, Tarek Hallal, et al.
Hepatology (Baltimore, Md.)|March 21, 2022
Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world studyAntonio D'Alessio, Claudia Angela Maria Fulgenzi, Naoshi Nishida, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|June 8, 2026
Validation of Risk Models for Predicting Post-SVR HCC in Real-World Surveillance Across Global Geographic RegionsHidenori Toyoda, Yujin Hoshida, Neehar D Parikh, et al.
Hepatology Communications|November 4, 2024
Atezolizumab/bevacizumab and lenvatinib for hepatocellular carcinoma: A comparative analysis in a European real-world cohortTiago de Castro, Sabrina Welland, Leonie Jochheim, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation|January 7, 2020
Repeated kidney re-transplantation-the Eurotransplant experience: a retrospective multicenter outcome analysisVolker Assfalg, Katharina Selig, Johanna Tolksdorf, et al.
Pageof 161